Top

Published in:

01-11-2021 | Epigenetics

The role and molecular mechanism of epigenetics in cardiac hypertrophy

Authors: Hao Lei, Jiahui Hu, Kaijun Sun, Danyan Xu

Published in: Heart Failure Reviews | Issue 6/2021

Abstract

Cardiac hypertrophy is a significant risk factor for cardiovascular disease, including heart failure, arrhythmia, and sudden death. Cardiac hypertrophy involves both embryonic gene expression and transcriptional reprogramming, which are tightly regulated by epigenetic mechanisms. An increasing number of studies have demonstrated that epigenetics plays an influential role in the occurrence and development of cardiac hypertrophy. Here, we summarize the latest research progress on epigenetics in cardiac hypertrophy involving DNA methylation, histone modification, and non-coding RNA, to help understand the mechanism of epigenetics in cardiac hypertrophy. The expression of both embryonic and functional genes can be precisely regulated by epigenetic mechanisms during cardiac hypertrophy, providing a substantial number of therapeutic targets. Thus, epigenetic treatment is expected to become a novel therapeutic strategy for cardiac hypertrophy. According to the research performed to date, epigenetic mechanisms associated with cardiac hypertrophy remain far from completely understood. Therefore, epigenetic mechanisms require further exploration to improve the prevention, diagnosis, and treatment of cardiac hypertrophy.

Sen P, Shah PP, Nativio R, Berger SL (2016) Epigenetic mechanisms of longevity and aging. Cell 166(4):822–839. https://doi.org/10.1016/j.cell.2016.07.050CrossRefPubMedPubMedCentral

Khyzha N, Alizada A, Wilson MD, Fish JE (2017) Epigenetics of atherosclerosis: emerging mechanisms and methods. Trends Mol Med 23(4):332–347. https://doi.org/10.1016/j.molmed.2017.02.004CrossRefPubMed

Keating ST, Plutzky J, El-Osta A (2016) Epigenetic changes in diabetes and cardiovascular risk. Circ Res 118(11):1706–1722. https://doi.org/10.1161/CIRCRESAHA.116.306819CrossRefPubMedPubMedCentral

Gamen E, Seeger W, Pullamsetti SS (2016) The emerging role of epigenetics in pulmonary hypertension. Eur Respir J 48(3):903–917. https://doi.org/10.1183/13993003.01714-2015CrossRefPubMed

Frey N, Katus HA, Olson EN, Hill JA (2004) Hypertrophy of the heart: a new therapeutic target? Circulation 109(13):1580–1589. https://doi.org/10.1161/01.CIR.0000120390.68287.BBCrossRefPubMed

Cotecchia S, Del Vescovo CD, Colella M, Caso S, Diviani D (2015) The alpha1-adrenergic receptors in cardiac hypertrophy: signaling mechanisms and functional implications. Cell Signal 27(10):1984–1993. https://doi.org/10.1016/j.cellsig.2015.06.009CrossRefPubMed

Zhang CL, McKinsey TA, Chang S, Antos CL, Hill JA, Olson EN (2002) Class II histone deacetylases act as signal-responsive repressors of cardiac hypertrophy. Cell 110(4):479–488. https://doi.org/10.1016/s0092-8674(02)00861-9CrossRefPubMedPubMedCentral

Carè A, Catalucci D, Felicetti F, Bonci D, Addario A, Gallo P, Bang M-L, Segnalini P, Gu Y, Dalton ND, Elia L, Latronico MVG, Høydal M, Autore C, Russo MA, Dorn GW 2nd, Ellingsen O, Ruiz-Lozano P, Peterson KL, Croce CM, Peschle C, Condorelli G (2007) MicroRNA-133 controls cardiac hypertrophy. Nat Med 13(5):613–618. https://doi.org/10.1038/nm1582CrossRefPubMed

Ziller MJ, Gu H, Müller F, Donaghey J, Tsai LTY, Kohlbacher O, De Jager PL, Rosen ED, Bennett DA, Bernstein BE, Gnirke A, Meissner A (2013) Charting a dynamic DNA methylation landscape of the human genome. Nature 500(7463):477–481. https://doi.org/10.1038/nature12433CrossRefPubMedPubMedCentral

10.

Okano M, Bell DW, Haber DA, Li E (1999) DNA methyltransferases Dnmt3a and Dnmt3b are essential for de novo methylation and mammalian development. Cell 99(3):247–257. https://doi.org/10.1016/s0092-8674(00)81656-6CrossRefPubMed

11.

Bourc'his D, Xu GL, Lin CS, Bollman B, Bestor TH (2001) Dnmt3L and the establishment of maternal genomic imprints. Science (New York, NY) 294(5551):2536–2539. https://doi.org/10.1126/science.1065848CrossRef

12.

Suetake I, Shinozaki F, Miyagawa J, Takeshima H, Tajima S (2004) DNMT3L stimulates the DNA methylation activity of Dnmt3a and Dnmt3b through a direct interaction. J Biol Chem 279(26):27816–27823. https://doi.org/10.1074/jbc.M400181200CrossRefPubMed

13.

Wu X, Zhang Y (2017) TET-mediated active DNA demethylation: mechanism, function and beyond. Nat Rev Genet 18(9):517–534. https://doi.org/10.1038/nrg.2017.33CrossRefPubMed

14.

Gilsbach R, Preissl S, Grüning BA, Schnick T, Burger L, Benes V, Würch A, Bönisch U, Günther S, Backofen R, Fleischmann BK, Schübeler D, Hein L (2014) Dynamic DNA methylation orchestrates cardiomyocyte development, maturation and disease. Nat Commun 5:5288. https://doi.org/10.1038/ncomms6288CrossRefPubMed

15.

Xiao D, Dasgupta C, Chen M, Zhang K, Buchholz J, Xu Z, Zhang L (2014) Inhibition of DNA methylation reverses norepinephrine-induced cardiac hypertrophy in rats. Cardiovasc Res 101(3):373–382. https://doi.org/10.1093/cvr/cvt264CrossRefPubMed

16.

Zhang Y, Yan W, Ji X, Yue H, Li G, Sang N (2018) Maternal NO2 exposure induces cardiac hypertrophy in male offspring via ROS-HIF-1alpha transcriptional regulation and aberrant DNA methylation modification of Csx/Nkx2.5. Arch Toxicol 92(4):1563–1579. https://doi.org/10.1007/s00204-018-2166-3CrossRefPubMed

17.

McCulley DJ, Black BL (2012) Transcription factor pathways and congenital heart disease. Curr Top Dev Biol 100:253–277. https://doi.org/10.1016/b978-0-12-387786-4.00008-7CrossRefPubMedPubMedCentral

18.

Yilbas AE, Hamilton A, Wang Y, Mach H, Lacroix N, Davis DR, Chen J, Li Q (2014) Activation of GATA4 gene expression at the early stage of cardiac specification. Front Chem 2:12. https://doi.org/10.3389/fchem.2014.00012CrossRefPubMedPubMedCentral

19.

Warren SA, Terada R, Briggs LE, Cole-Jeffrey CT, Chien WM, Seki T, Weinberg EO, Yang TP, Chin MT, Bungert J, Kasahara H (2011) Differential role of Nkx2-5 in activation of the atrial natriuretic factor gene in the developing versus failing heart. Mol Cell Biol 31(22):4633–4645. https://doi.org/10.1128/mcb.05940-11CrossRefPubMedPubMedCentral

20.

Chaturvedi P, Tyagi SC (2016) Epigenetic silencing of TIMP4 in heart failure. J Cell Mol Med 20(11):2089–2101. https://doi.org/10.1111/jcmm.12901CrossRefPubMedPubMedCentral

21.

Osadchii OE (2007) Cardiac hypertrophy induced by sustained beta-adrenoreceptor activation: pathophysiological aspects. Heart Fail Rev 12(1):66–86. https://doi.org/10.1007/s10741-007-9007-4CrossRefPubMed

22.

Fang X, Robinson J, Wang-Hu J, Jiang L, Freeman DA, Rivkees SA, Wendler CC (2015) cAMP induces hypertrophy and alters DNA methylation in HL-1 cardiomyocytes. Am J Physiol Cell Physiol 309(6):C425–C436. https://doi.org/10.1152/ajpcell.00058.2015CrossRefPubMedPubMedCentral

23.

Sasaki K, Hara S, Yamakami R, Sato Y, Hasegawa S, Kono T, Morohaku K, Obata Y (2019) Ectopic expression of DNA methyltransferases DNMT3A2 and DNMT3L leads to aberrant hypermethylation and postnatal lethality in mice. Mol Reprod Dev. https://doi.org/10.1002/mrd.23137

24.

Vujic A, Robinson EL, Ito M, Haider S, Ackers-Johnson M, See K, Methner C, Figg N, Brien P, Roderick HL, Skepper J, Ferguson-Smith A, Foo RS (2015) Experimental heart failure modelled by the cardiomyocyte-specific loss of an epigenome modifier, DNMT3B. J Mol Cell Cardiol 82:174–183. https://doi.org/10.1016/j.yjmcc.2015.03.007CrossRefPubMed

25.

Han P, Li W, Yang J, Shang C, Lin C-H, Cheng W, Hang CT, Cheng H-L, Chen C-H, Wong J, Xiong Y, Zhao M, Drakos SG, Ghetti A, Li DY, Bernstein D, Chen H-SV, Quertermous T, Chang C-P (2016) Epigenetic response to environmental stress: assembly of BRG1-G9a/GLP-DNMT3 repressive chromatin complex on Myh6 promoter in pathologically stressed hearts. Biochim Biophys Acta 1863(7 Pt B):1772–1781. https://doi.org/10.1016/j.bbamcr.2016.03.002CrossRefPubMedPubMedCentral

26.

Ciccarone F, Castelli S, Ioannilli L, Ciriolo MR (2019) High dietary fat intake affects DNA methylation/hydroxymethylation in mouse heart: epigenetic hints for obesity-related cardiac dysfunction. Mol Nutr Food Res 63(4):e1800970. https://doi.org/10.1002/mnfr.201800970CrossRefPubMed

27.

Chahrour M, Jung SY, Shaw C, Zhou X, Wong ST, Qin J, Zoghbi HY (2008) MeCP2, a key contributor to neurological disease, activates and represses transcription. Science (New York, NY) 320(5880):1224–1229. https://doi.org/10.1126/science.1153252CrossRef

28.

Mayer SC, Gilsbach R, Preissl S, Monroy Ordonez EB, Schnick T, Beetz N, Lother A, Rommel C, Ihle H, Bugger H, Ruhle F, Schrepper A, Schwarzer M, Heilmann C, Bonisch U, Gupta SK, Wilpert J, Kretz O, von Elverfeldt D, Orth J, Aktories K, Beyersdorf F, Bode C, Stiller B, Kruger M, Thum T, Doenst T, Stoll M, Hein L (2015) Adrenergic repression of the epigenetic reader MeCP2 facilitates cardiac adaptation in chronic heart failure. Circ Res 117(7):622–633. https://doi.org/10.1161/circresaha.115.306721CrossRefPubMedPubMedCentral

29.

Papait R, Serio S, Pagiatakis C, Rusconi F, Carullo P, Mazzola M, Salvarani N, Miragoli M, Condorelli G (2017) Histone methyltransferase G9a is required for cardiomyocyte homeostasis and hypertrophy. Circulation 136(13):1233–1246. https://doi.org/10.1161/circulationaha.117.028561CrossRefPubMed

30.

Thienpont B, Aronsen JM, Robinson EL, Okkenhaug H, Loche E, Ferrini A, Brien P, Alkass K, Tomasso A, Agrawal A, Bergmann O, Sjaastad I, Reik W, Roderick HL (2017) The H3K9 dimethyltransferases EHMT1/2 protect against pathological cardiac hypertrophy. J Clin Invest 127(1):335–348. https://doi.org/10.1172/JCI88353CrossRefPubMed

31.

Wang S, Wang C, Turdi S, Richmond KL, Zhang Y, Ren J (2018) ALDH2 protects against high fat diet-induced obesity cardiomyopathy and defective autophagy: role of CaM kinase II, histone H3K9 methyltransferase SUV39H, Sirt1, and PGC-1alpha deacetylation. Int J Obes 42(5):1073–1087. https://doi.org/10.1038/s41366-018-0030-4CrossRef

32.

Weng X, Yu L, Liang P, Li L, Dai X, Zhou B, Wu X, Xu H, Fang M, Chen Q, Xu Y (2015) A crosstalk between chromatin remodeling and histone H3K4 methyltransferase complexes in endothelial cells regulates angiotensin II-induced cardiac hypertrophy. J Mol Cell Cardiol 82:48–58. https://doi.org/10.1016/j.yjmcc.2015.02.010CrossRefPubMed

33.

Warren JS, Tracy CM, Miller MR, Makaju A, Szulik MW, Oka SI, Yuzyuk TN, Cox JE, Kumar A, Lozier BK, Wang L, Llana JG, Sabry AD, Cawley KM, Barton DW, Han YH, Boudina S, Fiehn O, Tucker HO, Zaitsev AV, Franklin S (2018) Histone methyltransferase Smyd1 regulates mitochondrial energetics in the heart. Proc Natl Acad Sci U S A 115(33):E7871–e7880. https://doi.org/10.1073/pnas.1800680115CrossRefPubMedPubMedCentral

34.

Franklin S, Kimball T, Rasmussen TL, Rosa-Garrido M, Chen H, Tran T, Miller MR, Gray R, Jiang S, Ren S, Wang Y, Tucker HO, Vondriska TM (2016) The chromatin-binding protein Smyd1 restricts adult mammalian heart growth. Am J Phys Heart Circ Phys 311(5):H1234–h1247. https://doi.org/10.1152/ajpheart.00235.2016CrossRef

35.

Yu L, Yang G, Weng X, Liang P, Li L, Li J, Fan Z, Tian W, Wu X, Xu H, Fang M, Ji Y, Li Y, Chen Q, Xu Y (2015) Histone methyltransferase SET1 mediates angiotensin II-induced endothelin-1 transcription and cardiac hypertrophy in mice. Arterioscler Thromb Vasc Biol 35(5):1207–1217. https://doi.org/10.1161/atvbaha.115.305230CrossRefPubMed

36.

Stein AB, Goonewardena SN, Jones TA, Prusick PJ, Bazzi AA, Belyavskaya JM, McCoskey MM, Dandar RA (2015) The PTIP-associated histone methyltransferase complex prevents stress-induced maladaptive cardiac remodeling. PLoS One 10(5):e0127839. https://doi.org/10.1371/journal.pone.0127839CrossRefPubMedPubMedCentral

37.

Zhou XL, Zhu RR, Wu X, Xu H, Li YY, Xu QR, Liu S, Huang H, Xu X, Wan L, Wu QC, Liu JC (2019) NSD2 promotes ventricular remodelling mediated by the regulation of H3K36me2. J Cell Mol Med 23(1):568–575. https://doi.org/10.1111/jcmm.13961CrossRefPubMed

38.

Rosales W, Lizcano F (2018) The histone demethylase JMJD2A modulates the induction of hypertrophy markers in iPSC-derived cardiomyocytes. Front Genet 9:14. https://doi.org/10.3389/fgene.2018.00014CrossRefPubMedPubMedCentral

39.

Wu X, Pan B, Liu L, Zhao W, Zhu J, Huang X, Tian J (2019) In utero exposure to PM2.5 during gestation caused adult cardiac hypertrophy through histone acetylation modification. J Cell Biochem 120(3):4375–4384. https://doi.org/10.1002/jcb.27723CrossRefPubMed

40.

Qiao W, Zhang W, Gai Y, Zhao L, Fan J (2014) The histone acetyltransferase MOF overexpression blunts cardiac hypertrophy by targeting ROS in mice. Biochem Biophys Res Commun 448(4):379–384. https://doi.org/10.1016/j.bbrc.2014.04.112CrossRefPubMed

41.

Morales CR, Li DL, Pedrozo Z, May HI, Jiang N, Kyrychenko V, Cho GW, Kim SY, Wang ZV, Rotter D, Rothermel BA, Schneider JW, Lavandero S, Gillette TG, Hill JA (2016) Inhibition of class I histone deacetylases blunts cardiac hypertrophy through TSC2-dependent mTOR repression. Sci Sign 9(422):ra34. https://doi.org/10.1126/scisignal.aad5736CrossRef

42.

Kee HJ, Sohn IS, Nam KI, Park JE, Qian YR, Yin Z, Ahn Y, Jeong MH, Bang YJ, Kim N, Kim JK, Kim KK, Epstein JA, Kook H (2006) Inhibition of histone deacetylation blocks cardiac hypertrophy induced by angiotensin II infusion and aortic banding. Circulation 113(1):51–59. https://doi.org/10.1161/circulationaha.105.559724CrossRefPubMed

43.

Trivedi CM, Luo Y, Yin Z, Zhang M, Zhu W, Wang T, Floss T, Goettlicher M, Noppinger PR, Wurst W, Ferrari VA, Abrams CS, Gruber PJ, Epstein JA (2007) Hdac2 regulates the cardiac hypertrophic response by modulating Gsk3 beta activity. Nat Med 13(3):324–331. https://doi.org/10.1038/nm1552CrossRefPubMed

44.

Montgomery RL, Potthoff MJ, Haberland M, Qi X, Matsuzaki S, Humphries KM, Richardson JA, Bassel-Duby R, Olson EN (2008) Maintenance of cardiac energy metabolism by histone deacetylase 3 in mice. J Clin Invest 118(11):3588–3597. https://doi.org/10.1172/jci35847CrossRefPubMedPubMedCentral

45.

Gregoire S, Xiao L, Nie J, Zhang X, Xu M, Li J, Wong J, Seto E, Yang XJ (2007) Histone deacetylase 3 interacts with and deacetylates myocyte enhancer factor 2. Mol Cell Biol 27(4):1280–1295. https://doi.org/10.1128/mcb.00882-06CrossRefPubMed

46.

Zhang CL, McKinsey TA, Olson EN (2002) Association of class II histone deacetylases with heterochromatin protein 1: potential role for histone methylation in control of muscle differentiation. Mol Cell Biol 22(20):7302–7312. https://doi.org/10.1128/mcb.22.20.7302-7312.2002CrossRefPubMedPubMedCentral

47.

Song K, Backs J, McAnally J, Qi X, Gerard RD, Richardson JA, Hill JA, Bassel-Duby R, Olson EN (2006) The transcriptional coactivator CAMTA2 stimulates cardiac growth by opposing class II histone deacetylases. Cell 125(3):453–466. https://doi.org/10.1016/j.cell.2006.02.048CrossRefPubMed

48.

Tang X, Chen XF, Wang NY, Wang XM, Liang ST, Zheng W, Lu YB, Zhao X, Hao DL, Zhang ZQ, Zou MH, Liu DP, Chen HZ (2017) SIRT2 acts as a cardioprotective deacetylase in pathological cardiac hypertrophy. Circulation 136(21):2051–2067. https://doi.org/10.1161/circulationaha.117.028728CrossRefPubMedPubMedCentral

49.

Guo L, Yin A, Zhang Q, Zhong T, O'Rourke ST, Sun C (2017) Angiotensin-(1-7) attenuates angiotensin II-induced cardiac hypertrophy via a Sirt3-dependent mechanism. Am J Phys Heart Circ Phys 312(5):H980–h991. https://doi.org/10.1152/ajpheart.00768.2016CrossRef

50.

Li Z, Zhang X, Guo Z, Zhong Y, Wang P, Li J, Li Z, Liu P (2018) SIRT6 suppresses NFATc4 expression and activation in cardiomyocyte hypertrophy. Front Pharmacol 9:1519. https://doi.org/10.3389/fphar.2018.01519CrossRefPubMed

51.

Awad S, Al-Haffar KM, Marashly Q, Quijada P, Kunhi M, Al-Yacoub N, Wade FS, Mohammed SF, Al-Dayel F, Sutherland G, Assiri A, Sussman M, Bers D, Al-Habeeb W, Poizat C (2015) Control of histone H3 phosphorylation by CaMKIIδ in response to haemodynamic cardiac stress. J Pathol 235(4):606–618. https://doi.org/10.1002/path.4489CrossRefPubMed

52.

Klose RJ, Kallin EM, Zhang Y (2006) JmjC-domain-containing proteins and histone demethylation. Nat Rev Genet 7(9):715–727. https://doi.org/10.1038/nrg1945CrossRefPubMed

53.

Papait R, Cattaneo P, Kunderfranco P, Greco C, Carullo P, Guffanti A, Viganò V, Stirparo GG, Latronico MV, Hasenfuss G, Chen J, Condorelli G (2013) Genome-wide analysis of histone marks identifying an epigenetic signature of promoters and enhancers underlying cardiac hypertrophy. Proc Natl Acad Sci U S A 110(50):20164–20169. https://doi.org/10.1073/pnas.1315155110CrossRefPubMedPubMedCentral

54.

Krauss V (2008) Glimpses of evolution: heterochromatic histone H3K9 methyltransferases left its marks behind. Genetica 133(1):93–106. https://doi.org/10.1007/s10709-007-9184-zCrossRefPubMed

55.

Gottlieb PD, Pierce SA, Sims RJ, Yamagishi H, Weihe EK, Harriss JV, Maika SD, Kuziel WA, King HL, Olson EN, Nakagawa O, Srivastava D (2002) Bop encodes a muscle-restricted protein containing MYND and SET domains and is essential for cardiac differentiation and morphogenesis. Nat Genet 31(1):25–32. https://doi.org/10.1038/ng866CrossRefPubMed

56.

Weng X, Yu L, Liang P, Chen D, Cheng X, Yang Y, Li L, Zhang T, Zhou B, Wu X, Xu H, Fang M, Gao Y, Chen Q, Xu Y (2015) Endothelial MRTF-A mediates angiotensin II induced cardiac hypertrophy. J Mol Cell Cardiol 80:23–33. https://doi.org/10.1016/j.yjmcc.2014.11.009CrossRefPubMed

57.

Zentner GE, Henikoff S (2013) Regulation of nucleosome dynamics by histone modifications. Nat Struct Mol Biol 20(3):259–266. https://doi.org/10.1038/nsmb.2470CrossRefPubMed

58.

de Ruijter AJM, van Gennip AH, Caron HN, Kemp S, van Kuilenburg ABP (2003) Histone deacetylases (HDACs): characterization of the classical HDAC family. Biochem J 370(Pt 3):737–749. https://doi.org/10.1042/BJ20021321CrossRefPubMedPubMedCentral

59.

Hasan S, Hottiger MO (2002) Histone acetyl transferases: a role in DNA repair and DNA replication. J Mol Med (Berlin, Germany) 80(8):463–474. https://doi.org/10.1007/s00109-002-0341-7CrossRef

60.

Gregoretti IV, Lee Y-M, Goodson HV (2004) Molecular evolution of the histone deacetylase family: functional implications of phylogenetic analysis. J Mol Biol 338(1):17–31. https://doi.org/10.1016/j.jmb.2004.02.006CrossRefPubMed

61.

Gao L, Cueto MA, Asselbergs F, Atadja P (2002) Cloning and functional characterization of HDAC11, a novel member of the human histone deacetylase family. J Biol Chem 277(28):25748–25755. https://doi.org/10.1074/jbc.M111871200CrossRefPubMed

62.

Chang S, McKinsey TA, Zhang CL, Richardson JA, Hill JA, Olson EN (2004) Histone deacetylases 5 and 9 govern responsiveness of the heart to a subset of stress signals and play redundant roles in heart development. Mol Cell Biol 24(19):8467–8476. https://doi.org/10.1128/MCB.24.19.8467-8476.2004CrossRefPubMedPubMedCentral

63.

Hohl M, Wagner M, Reil JC, Muller SA, Tauchnitz M, Zimmer AM, Lehmann LH, Thiel G, Bohm M, Backs J, Maack C (2013) HDAC4 controls histone methylation in response to elevated cardiac load. J Clin Invest 123(3):1359–1370. https://doi.org/10.1172/jci61084CrossRefPubMedPubMedCentral

64.

Chandrasekaran S, Peterson RE, Mani SK, Addy B, Buchholz AL, Xu L, Thiyagarajan T, Kasiganesan H, Kern CB, Menick DR (2009) Histone deacetylases facilitate sodium/calcium exchanger up-regulation in adult cardiomyocytes. FASEB J 23(11):3851–3864. https://doi.org/10.1096/fj.09-132415CrossRefPubMedPubMedCentral

65.

Sun W, Liu C, Chen Q, Liu N, Yan Y, Liu B (2018) SIRT3: a new regulator of cardiovascular diseases. Oxidative Med Cell Longev 2018:7293861. https://doi.org/10.1155/2018/7293861CrossRef

66.

Yu L, Gong B, Duan W, Fan C, Zhang J, Li Z, Xue X, Xu Y, Meng D, Li B, Zhang M, Bin Z, Jin Z, Yu S, Yang Y, Wang H (2017) Melatonin ameliorates myocardial ischemia/reperfusion injury in type 1 diabetic rats by preserving mitochondrial function: role of AMPK-PGC-1α-SIRT3 signaling. Sci Rep 7:41337. https://doi.org/10.1038/srep41337CrossRefPubMedPubMedCentral

67.

Hafner AV, Dai J, Gomes AP, Xiao CY, Palmeira CM, Rosenzweig A, Sinclair DA (2010) Regulation of the mPTP by SIRT3-mediated deacetylation of CypD at lysine 166 suppresses age-related cardiac hypertrophy. Aging 2(12):914–923. https://doi.org/10.18632/aging.100252CrossRefPubMedPubMedCentral

68.

Planavila A, Iglesias R, Giralt M, Villarroya F (2011) Sirt1 acts in association with PPARalpha to protect the heart from hypertrophy, metabolic dysregulation, and inflammation. Cardiovasc Res 90(2):276–284. https://doi.org/10.1093/cvr/cvq376CrossRefPubMed

69.

Lu Y, Wang YD, Wang XY, Chen H, Cai ZJ, Xiang MX (2016) SIRT3 in cardiovascular diseases: emerging roles and therapeutic implications. Int J Cardiol 220:700–705. https://doi.org/10.1016/j.ijcard.2016.06.236CrossRefPubMed

70.

Bode AM, Dong Z (2005) Inducible covalent posttranslational modification of histone H3. Science’s STKE 2005(281):re4-re4. https://doi.org/10.1126/stke.2812005re4CrossRef

71.

Liew CC, Sole MJ (1978) Studies of nuclear proteins in the heart of the cardiomyopathic Syrian hamster--phosphorylation of histones. J Mol Cell Cardiol 10(9):847–855. https://doi.org/10.1016/0022-2828(78)90393-0CrossRefPubMed

72.

Awad S, Kunhi M, Little GH, Bai Y, An W, Bers D, Kedes L, Poizat C (2013) Nuclear CaMKII enhances histone H3 phosphorylation and remodels chromatin during cardiac hypertrophy. Nucleic Acids Res 41(16):7656–7672. https://doi.org/10.1093/nar/gkt500CrossRefPubMedPubMedCentral

73.

Narlikar GJ, Sundaramoorthy R, Owen-Hughes T (2013) Mechanisms and functions of ATP-dependent chromatin-remodeling enzymes. Cell 154(3):490–503. https://doi.org/10.1016/j.cell.2013.07.011CrossRefPubMedPubMedCentral

74.

Mehrotra A, Joe B, de la Serna IL (2013) SWI/SNF chromatin remodeling enzymes are associated with cardiac hypertrophy in a genetic rat model of hypertension. J Cell Physiol 228(12):2337–2342. https://doi.org/10.1002/jcp.24404CrossRefPubMed

75.

Chang L, Kiriazis H, Gao X-M, Du X-J, El-Osta A (2011) Cardiac genes show contextual SWI/SNF interactions with distinguishable gene activities. Epigenetics 6(6):760–768. https://doi.org/10.4161/epi.6.6.16007CrossRefPubMed

76.

Hang CT, Yang J, Han P, Cheng HL, Shang C, Ashley E, Zhou B, Chang CP (2010) Chromatin regulation by Brg1 underlies heart muscle development and disease. Nature 466(7302):62–67. https://doi.org/10.1038/nature09130CrossRefPubMedPubMedCentral

77.

van Berlo JH (2015) Chromatin remodeling permits cardiac hypertrophy to develop. J Mol Cell Cardiol 89(Pt B):119–121. https://doi.org/10.1016/j.yjmcc.2015.10.033CrossRefPubMed

78.

Mehta G, Kumarasamy S, Wu J, Walsh A, Liu L, Williams K, Joe B, de la Serna IL (2015) MITF interacts with the SWI/SNF subunit, BRG1, to promote GATA4 expression in cardiac hypertrophy. J Mol Cell Cardiol 88:101–110. https://doi.org/10.1016/j.yjmcc.2015.09.010CrossRefPubMedPubMedCentral

79.

Cui H, Schlesinger J, Schoenhals S, Tonjes M, Dunkel I, Meierhofer D, Cano E, Schulz K, Berger MF, Haack T, Abdelilah-Seyfried S, Bulyk ML, Sauer S, Sperling SR (2016) Phosphorylation of the chromatin remodeling factor DPF3a induces cardiac hypertrophy through releasing HEY repressors from DNA. Nucleic Acids Res 44(6):2538–2553. https://doi.org/10.1093/nar/gkv1244CrossRefPubMed

80.

Iyer MK, Niknafs YS, Malik R, Singhal U, Sahu A, Hosono Y, Barrette TR, Prensner JR, Evans JR, Zhao S, Poliakov A, Cao X, Dhanasekaran SM, Wu YM, Robinson DR, Beer DG, Feng FY, Iyer HK, Chinnaiyan AM (2015) The landscape of long noncoding RNAs in the human transcriptome. Nat Genet 47(3):199–208. https://doi.org/10.1038/ng.3192CrossRefPubMedPubMedCentral

81.

Joladarashi D, Thandavarayan RA, Babu SS, Krishnamurthy P (2014) Small engine, big power: microRNAs as regulators of cardiac diseases and regeneration. Int J Mol Sci 15(9):15891–15911. https://doi.org/10.3390/ijms150915891CrossRefPubMedPubMedCentral

82.

Ikeda S, He A, Kong SW, Lu J, Bejar R, Bodyak N, Lee KH, Ma Q, Kang PM, Golub TR, Pu WT (2009) MicroRNA-1 negatively regulates expression of the hypertrophy-associated calmodulin and Mef2a genes. Mol Cell Biol 29(8):2193–2204. https://doi.org/10.1128/mcb.01222-08CrossRefPubMedPubMedCentral

83.

Ganesan J, Ramanujam D, Sassi Y, Ahles A, Jentzsch C, Werfel S, Leierseder S, Loyer X, Giacca M, Zentilin L, Thum T, Laggerbauer B, Engelhardt S (2013) MiR-378 controls cardiac hypertrophy by combined repression of mitogen-activated protein kinase pathway factors. Circulation 127(21):2097–2106. https://doi.org/10.1161/circulationaha.112.000882CrossRefPubMed

84.

Duan Y, Zhou B, Su H, Liu Y, Du C (2013) miR-150 regulates high glucose-induced cardiomyocyte hypertrophy by targeting the transcriptional co-activator p300. Exp Cell Res 319(3):173–184. https://doi.org/10.1016/j.yexcr.2012.11.015CrossRefPubMed

85.

Yang Y, Ago T, Zhai P, Abdellatif M, Sadoshima J (2011) Thioredoxin 1 negatively regulates angiotensin II-induced cardiac hypertrophy through upregulation of miR-98/let-7. Circ Res 108(3):305–313. https://doi.org/10.1161/circresaha.110.228437CrossRefPubMed

86.

Wei L, Yuan M, Zhou R, Bai Q, Zhang W, Zhang M, Huang Y, Shi L (2015) MicroRNA-101 inhibits rat cardiac hypertrophy by targeting Rab1a. J Cardiovasc Pharmacol 65(4):357–363. https://doi.org/10.1097/fjc.0000000000000203CrossRefPubMed

87.

Han M, Yang Z, Sayed D, He M, Gao S, Lin L, Yoon S, Abdellatif M (2012) GATA4 expression is primarily regulated via a miR-26b-dependent post-transcriptional mechanism during cardiac hypertrophy. Cardiovasc Res 93(4):645–654. https://doi.org/10.1093/cvr/cvs001CrossRefPubMedPubMedCentral

88.

Li R, Yan G, Zhang Q, Jiang Y, Sun H, Hu Y, Sun J, Xu B (2013) miR-145 inhibits isoproterenol-induced cardiomyocyte hypertrophy by targeting the expression and localization of GATA6. FEBS Lett 587(12):1754–1761. https://doi.org/10.1016/j.febslet.2013.04.018CrossRefPubMedPubMedCentral

89.

Dey N, Ghosh-Choudhury N, Kasinath BS, Choudhury GG (2012) TGFβ-stimulated microRNA-21 utilizes PTEN to orchestrate AKT/mTORC1 signaling for mesangial cell hypertrophy and matrix expansion. PLoS One 7(8):e42316. https://doi.org/10.1371/journal.pone.0042316CrossRefPubMedPubMedCentral

90.

Huang ZP, Chen J, Seok HY, Zhang Z, Kataoka M, Hu X, Wang DZ (2013) MicroRNA-22 regulates cardiac hypertrophy and remodeling in response to stress. Circ Res 112(9):1234–1243. https://doi.org/10.1161/circresaha.112.300682CrossRefPubMedPubMedCentral

91.

Li Z, Song Y, Liu L, Hou N, An X, Zhan D, Li Y, Zhou L, Li P, Yu L, Xia J, Zhang Y, Wang J, Yang X (2017) miR-199a impairs autophagy and induces cardiac hypertrophy through mTOR activation. Cell Death Differ 24(7):1205–1213. https://doi.org/10.1038/cdd.2015.95CrossRefPubMed

92.

Ucar A, Gupta SK, Fiedler J, Erikci E, Kardasinski M, Batkai S, Dangwal S, Kumarswamy R, Bang C, Holzmann A, Remke J, Caprio M, Jentzsch C, Engelhardt S, Geisendorf S, Glas C, Hofmann TG, Nessling M, Richter K, Schiffer M, Carrier L, Napp LC, Bauersachs J, Chowdhury K, Thum T (2012) The miRNA-212/132 family regulates both cardiac hypertrophy and cardiomyocyte autophagy. Nat Commun 3:1078. https://doi.org/10.1038/ncomms2090CrossRefPubMed

93.

Li C, Li X, Gao X, Zhang R, Zhang Y, Liang H, Xu C, Du W, Zhang Y, Liu X, Ma N, Xu Z, Wang L, Chen X, Lu Y, Ju J, Yang B, Shan H (2014) MicroRNA-328 as a regulator of cardiac hypertrophy. Int J Cardiol 173(2):268–276. https://doi.org/10.1016/j.ijcard.2014.02.035CrossRefPubMed

94.

Song DW, Ryu JY, Kim JO, Kwon EJ, Kim DH (2014) The miR-19a/b family positively regulates cardiomyocyte hypertrophy by targeting atrogin-1 and MuRF-1. Biochem J 457(1):151–162. https://doi.org/10.1042/bj20130833CrossRefPubMed

95.

Lai Y, He S, Ma L, Lin H, Ren B, Ma J, Zhu X, Zhuang S (2017) HOTAIR functions as a competing endogenous RNA to regulate PTEN expression by inhibiting miR-19 in cardiac hypertrophy. Mol Cell Biochem 432(1–2):179–187. https://doi.org/10.1007/s11010-017-3008-yCrossRefPubMed

96.

Lv L, Li T, Li X, Xu C, Liu Q, Jiang H, Li Y, Liu Y, Yan H, Huang Q, Zhou Y, Zhang M, Shan H, Liang H (2018) The lncRNA Plscr4 controls cardiac hypertrophy by regulating miR-214. Mol Ther Nucl Acids 10:387–397. https://doi.org/10.1016/j.omtn.2017.12.018CrossRef

97.

Han P, Li W, Lin CH, Yang J, Shang C, Nuernberg ST, Jin KK, Xu W, Lin CY, Lin CJ, Xiong Y, Chien H, Zhou B, Ashley E, Bernstein D, Chen PS, Chen HV, Quertermous T, Chang CP (2014) A long noncoding RNA protects the heart from pathological hypertrophy. Nature 514(7520):102–106. https://doi.org/10.1038/nature13596CrossRefPubMedPubMedCentral

98.

Zhou G, Li C, Feng J, Zhang J, Fang Y (2018) lncRNA UCA1 is a novel regulator in cardiomyocyte hypertrophy through targeting the miR-184/HOXA9 Axis. Cardiorenal Med 8(2):130–139. https://doi.org/10.1159/000487204CrossRefPubMedPubMedCentral

99.

Wang K, Liu F, Zhou LY, Long B, Yuan SM, Wang Y, Liu CY, Sun T, Zhang XJ, Li PF (2014) The long noncoding RNA CHRF regulates cardiac hypertrophy by targeting miR-489. Circ Res 114(9):1377–1388. https://doi.org/10.1161/circresaha.114.302476CrossRefPubMed

100.

Viereck J, Kumarswamy R, Foinquinos A, Xiao K, Avramopoulos P, Kunz M, Dittrich M, Maetzig T, Zimmer K, Remke J, Just A, Fendrich J, Scherf K, Bolesani E, Schambach A, Weidemann F, Zweigerdt R, de Windt LJ, Engelhardt S, Dandekar T, Batkai S, Thum T (2016) Long noncoding RNA Chast promotes cardiac remodeling. Sci Transl Med 8(326):326ra322. https://doi.org/10.1126/scitranslmed.aaf1475CrossRef

101.

Wang K, Long B, Liu F, Wang JX, Liu CY, Zhao B, Zhou LY, Sun T, Wang M, Yu T, Gong Y, Liu J, Dong YH, Li N, Li PF (2016) A circular RNA protects the heart from pathological hypertrophy and heart failure by targeting miR-223. Eur Heart J 37(33):2602–2611. https://doi.org/10.1093/eurheartj/ehv713CrossRefPubMed

102.

Mathiyalagan P, Okabe J, Chang L, Su Y, Du XJ, El-Osta A (2014) The primary microRNA-208b interacts with polycomb-group protein, Ezh2, to regulate gene expression in the heart. Nucleic Acids Res 42(2):790–803. https://doi.org/10.1093/nar/gkt896CrossRefPubMed

103.

Wang Z, Zhang XJ, Ji YX, Zhang P, Deng KQ, Gong J, Ren S, Wang X, Chen I, Wang H, Gao C, Yokota T, Ang YS, Li S, Cass A, Vondriska TM, Li G, Deb A, Srivastava D, Yang HT, Xiao X, Li H, Wang Y (2016) The long noncoding RNA Chaer defines an epigenetic checkpoint in cardiac hypertrophy. Nat Med 22(10):1131–1139. https://doi.org/10.1038/nm.4179CrossRefPubMedPubMedCentral

104.

Kook H, Lepore JJ, Gitler AD, Lu MM, Wing-Man Yung W, Mackay J, Zhou R, Ferrari V, Gruber P, Epstein JA (2003) Cardiac hypertrophy and histone deacetylase-dependent transcriptional repression mediated by the atypical homeodomain protein Hop. J Clin Invest 112(6):863–871. https://doi.org/10.1172/JCI19137CrossRefPubMedPubMedCentral

105.

Raghunathan S, Goyal RK, Patel BM (2017) Selective inhibition of HDAC2 by magnesium valproate attenuates cardiac hypertrophy. Can J Physiol Pharmacol 95(3):260–267. https://doi.org/10.1139/cjpp-2016-0542CrossRefPubMed

Title: The role and molecular mechanism of epigenetics in cardiac hypertrophy
Authors: Hao Lei
Jiahui Hu
Kaijun Sun
Danyan Xu
Publication date: 01-11-2021
Publisher: Springer US
Keyword: Epigenetics
Published in: Heart Failure Reviews / Issue 6/2021
Print ISSN: 1382-4147
Electronic ISSN: 1573-7322
DOI: https://doi.org/10.1007/s10741-020-09959-3

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Keynote webinar | Spotlight on medication adherence

Springer Medicine

The role and molecular mechanism of epigenetics in cardiac hypertrophy

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 6/2021

Editorial Expression of Concern: Water and sodium in heart failure: a spotlight on congestion

Crosstalk between GSK-3β-actuated molecular cascades and myocardial physiology

Peripartum cardiomyopathy: a review

A right ventricular state of mind in the progression of heart failure with reduced ejection fraction: implications for left ventricular assist device therapy

Comprehensive assessment of hypertensive heart disease: cardiac magnetic resonance in focus

Distinctive patterns of inflammation across the heart failure syndrome

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page